Everything We've Written
All of it — compound guides, protocol breakdowns, research notes. Use the tags to find what you're after.
6 articles publishedRetatrutide at ADA 2026: Triple-Agonist vs. Tirzepatide
ADA 2026 may bring new retatrutide data, but head-to-head trials against tirzepatide are still missing. We examine what clinicians need to know about
Tirzepatide Medicare Coverage: What July 1 Means for Access
Medicare Part D will cover tirzepatide for weight loss starting July 1, 2025, expanding access for older adults. This article examines the policy's implications
Retatrutide and Bone Health: Could the Triple-Agonist Offer Greater Skeletal Protection Than Semaglutide?
Retatrutide's triple-agonist mechanism raises questions about bone protection versus semaglutide, but human data are absent. We examine what studies
Tirzepatide First-Line Status: ACP Obesity Guidelines 2025
ACP's 2025 guidelines elevate tirzepatide to first-line obesity treatment. We examine dosing protocols, female-specific metabolic considerations, and unanswered questions in reproductive-age cohorts.
Tirzepatide and Lean Muscle Preservation in GLP-1 Research
Tirzepatide shows a modest improvement in lean-to-fat loss ratio versus GLP-1 monotherapy, but absolute muscle loss remains significant and female-specific data are sparse.
Tirzepatide vs. GLP-1: Why Telehealth Shifts to Dual-Action
Telehealth platforms are adopting tirzepatide and retatrutide for weight loss, citing higher efficacy than GLP-1 monotherapy, but female-specific data and long-term safety remain limited.